Texas Capital Bank Wealth Management Services Inc Boosts Stock Position in Zoetis Inc. $ZTS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 24.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,783 shares of the company's stock after purchasing an additional 10,091 shares during the period. Zoetis accounts for about 0.9% of Texas Capital Bank Wealth Management Services Inc's portfolio, making the stock its 24th biggest position. Texas Capital Bank Wealth Management Services Inc's holdings in Zoetis were worth $8,526,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Navigoe LLC bought a new stake in Zoetis in the fourth quarter worth $30,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Sound Income Strategies LLC boosted its stake in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares during the period. Finally, Bfsg LLC grew its holdings in Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after purchasing an additional 252 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.8%

ZTS traded down $1.2650 during trading on Thursday, hitting $155.4950. 2,411,616 shares of the stock were exchanged, compared to its average volume of 3,540,633. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a 50 day simple moving average of $154.00 and a 200 day simple moving average of $158.75. The firm has a market cap of $68.91 billion, a price-to-earnings ratio of 26.76, a P/E/G ratio of 2.52 and a beta of 0.88. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ZTS shares. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.